REGN (US)

Amid reports that HHS is considering steps to curtail direct-to-consumer (DTC) drug advertisements – with negative implications for high spenders in this area [ABBV, NVO, REGN] – we see significant impediments to how far /…

Investors should view today’s drug pricing Executive Order (EO) with relief, and while the biopharma industry remains on notice for potential future regulatory actions, we suspect the courts would intervene to stop any overly broad…

We continue to believe that full expensing / deductibility of the R&D tax credit in the year expenses occur will be part of the massive reconciliation / tax bill we expect to see enacted in…